Core Viewpoint - The company Bai Aosai Tu-B (02315) has successfully listed on the Sci-Tech Innovation Board, establishing a dual-platform listing structure of "H+A" after its previous listing on the Hong Kong Stock Exchange in September 2022, which is a significant step in enhancing its capital market presence and corporate value [1] Group 1: Stock Performance - Bai Aosai Tu-B's stock rose over 5% during trading, with a current increase of 4.15%, priced at 28.12 HKD, and a trading volume of 19.5098 million HKD [1] Group 2: Business Strategy - The company initiated the "Thousand Mice, Ten Thousand Antibodies" plan in March 2020, utilizing an "antibody shelf" model that reduces R&D time and lowers early-stage R&D uncertainties, while also improving the efficiency and success rate of clinical transformations for pharmaceutical companies [1] - The antibody business started in 2020, generating revenue of 0.41 million CNY in its first year, with revenue reaching 1.63 million CNY in the first half of 2025, reflecting a year-on-year growth of 37.8% [1] - As further molecular developments progress in clinical trials, the company's platform value is expected to increase significantly [1]

Core Viewpoint - Baiaosaitu-B (02315) has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, marking a significant step in enhancing its capital market presence and corporate value, establishing a dual-platform listing structure with its previous listing on the Hong Kong Stock Exchange on September 1, 2022 [1] Group 1 - Baiaosaitu-B's stock price increased by over 5% during trading, with a current rise of 4.15%, reaching HKD 28.12, and a trading volume of HKD 19.5098 million [1] - The company initiated the "Thousand Mice and Ten Thousand Antibodies" plan in March 2020, which has streamlined research and development timelines and reduced early-stage R&D uncertainties [1] - The antibody business generated revenue of CNY 0.41 billion in 2020, with revenue reaching CNY 1.63 billion in the first half of 2025, reflecting a year-on-year growth of 37.8% [1]

Core Viewpoint - Baiaosaitu-B (02315) has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 10, marking a significant step in enhancing its capital market presence and corporate value, establishing a dual-platform listing structure with its previous listing on the Hong Kong Stock Exchange on September 1, 2022 [1] Group 1: Company Performance - Baiaosaitu's stock price increased by over 5% during trading, closing at 28.12 HKD with a trading volume of 19.51 million HKD [1] - The company's antibody business, initiated in March 2020, generated revenue of 0.41 million CNY in its first year, with revenue reaching 1.63 million CNY in the first half of 2025, reflecting a year-on-year growth of 37.8% [1] Group 2: Strategic Initiatives - The company launched the "Thousand Mice and Ten Thousand Antibodies" initiative, which aims to save research and development time and reduce early-stage R&D uncertainties while improving the efficiency and success rate of clinical transformations for pharmaceutical companies [1] - The platform's value is expected to further amplify as subsequent molecules advance in clinical trials [1]

Core Viewpoint - JingTai Holdings (02228) reported a significant turnaround in its interim results for the six months ending June 30, 2025, with a revenue of 517 million RMB, marking a year-on-year increase of 403.83% and a net profit attributable to shareholders of 82.795 million RMB, compared to a loss of 1.237 billion RMB in the same period last year [1] Financial Performance - Revenue for the drug discovery solutions business surged from 60.9 million RMB for the six months ending June 30, 2024, to 435 million RMB for the same period in 2025, reflecting a growth of 615.2% [1] - The company achieved a monthly average cash burn reduction of 20.0%, bringing it down to 49.7 million RMB [1] - Adjusted net profit for the first half of the year reached 142 million RMB, marking the first time the company achieved half-year profitability [1] Strategic Developments - The revenue growth was primarily driven by a significant collaboration with DoveTree Medicines LLC and its affiliates, with the company reaching the first milestone of this partnership and receiving an initial payment of 51 million USD [1] - The company ended the reporting period with a cash balance of 5.308 billion RMB, indicating a strong financial position [1]

Core Viewpoint - Crystal Tech Holdings (02228) reported a significant turnaround in its financial performance for the six months ending June 30, 2025, with a revenue increase of 403.83% year-on-year, reaching 517 million RMB, and a shift from a loss of 1.237 billion RMB to a profit of 82.795 million RMB for shareholders [1] Financial Performance - Revenue for the drug discovery solutions business surged by 615.2%, from 60.9 million RMB for the six months ending June 30, 2024, to 435 million RMB for the same period in 2025, primarily driven by a major collaboration with DoveTree Medicines LLC [1] - The company achieved a milestone in its collaboration with DoveTree, receiving an initial payment of 51 million USD [1] - The antibody business also demonstrated strong revenue growth during the reporting period [1] Cash Position and Profitability - As of the end of the reporting period, the company had a cash balance of 5.308 billion RMB, indicating a solid financial position [1] - Monthly average cash consumption decreased by 20.0% to 49.7 million RMB during the first half of the year [1] - The adjusted net profit for the first half of the year was 142 million RMB, marking the first time the company achieved half-year profitability, signifying a new growth phase for the company [1]